Organic Chemical – Page 45

Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.

CSL Vifor’s Corrective Marketing Initiative to Address Anti-Competitive Concerns

1 year ago talkbio0Tagged anti-competitive practices, competition, Corrective, CSHL1 gene, Drug Industry, fairness, Market, Measures, Vifor

CSL Vifor, marketing campaign, anti-competitive practices, competition law, corrective measures, pharmaceutical industry, competition watchdog, market fairness.

Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment

1 year ago talkbio0Tagged Alecensa, Approved, Malignant neoplasm of lung, Postsurgical, Roche (company), United States Food and Drug Administration

Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer

AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline

1 year ago talkbio0Tagged AbbVie, Approved, Crohn 's disease, Drops - Drug Form, Humira, Immunology, Inhibitor, J&J, Janus kinase, Physicians ' ranking, Players, Rinvoq, United States Food and Drug Administration

AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

Cerevel Reports Phase 3 Parkinson’s Study Success Amidst AbbVie Acquisition

1 year ago talkbio0Tagged AbbVie Acquisition, Cerevel, Clinical Trials, Parkinson 's disease trial, Phase 3, Tavapadon

Cerevel Therapeutics, Phase 3 Parkinson’s disease trial, Tavapadon, AbbVie acquisition, Successful clinical trial results

Intra-Cellular’s Caplyta Triumphs in Major Depressive Disorder Phase 3 Trial, Edging Closer to FDA Filing

1 year ago talkbio0Tagged Caplyta, CGI-S, Clinical Global Impression Original Version Questionnaire, clinically, File (record), Intra-Cellular Therapies, Lumateperone, MADRS, MDD, Montgomery-Åsberg depression rating scale, Phase 3 trial, Positive, results, Severities, Statistical Significance, Unipolar Depression, United States Food and Drug Administration

Intra-Cellular Therapies, Caplyta, Lumateperone, Major Depressive Disorder (MDD), Phase 3 Trial, Positive Results, Statistically Significant, Clinically Meaningful, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale for Severity of Illness (CGI-S), FDA Filing